ISEB 1010, 419 Physical Sciences Quad, Irvine, CA, United States
Location: ISEB 1010
Speaker
Dan Nomura, Ph.D. UC Berkley
Title
Reimagining Druggability using Chemoproteomic Platforms
Abstract
The Nomura Research Group is focused on reimagining druggability using chemoproteomic platforms to developtransformative medicines. One of the greatest challenges that we face in discovering new disease therapies is thatmost proteins are considered “undruggable,” in that most proteins do not possess known binding pockets or”ligandable hotspots” that small-molecules can bind to modulate protein function. Our research group addresses thischallenge by advancing and applying chemoproteomic platforms to discover and pharmacologically target uniqueand novel ligandable hotspots for disease therapy. We currently have three major research directions. Our firstmajor focus is on developing and applying chemoproteomics-enabled covalent ligand discovery approaches torapidly discover small-molecule therapeutic leads that target unique and novel ligandable hotspots for undruggableprotein targets and pathways. Our second research area focuses on using chemoproteomic platforms to expand thescope of targeted protein degradation technologies. Our third research area focuses on using chemoproteomics-enabled covalent ligand discovery platforms to develop new induced proximity-based therapeutic modalities.Collectively, our lab is focused on developing next-generation transformative medicines through pioneeringinnovative chemical technologies to overcome challenges in drug discovery.